SRY-related HMG-box gene 2 (SOX2) is one of the key regulatory genes that maintain the pluripotency and self-renewal properties in embryonic stem cells.
Introduction SRY-related HMG-box gene 2 (SOX2) was initially reported to be strongly associated with the inhibition of neuronal differentiation (Bylund et al., 2003) . More recent studies indicated that SOX2 exits in the nuclei of embryonic stem (ES) cells and acts as a transcriptional factor to maintain the unique characters such as clonogenicity, pluripotency, and self-renewal of them (Takahashi and Yamanaka, 2006; Masui et al., 2007; Wernig et al., 2007; Park et al., 2008) . The concept of cancer stem cell (CSC) was raised by the observation that a small percentage of cancer cell population has the same characters as ES cells (Garcia-Barrado et al., 2001) . CSCs were isolated in various types of cultured cancer cells and tumors by the Hoechst efflux method or by use of various stem cell surface markers, such as CD34, CD138, CD20, CD133, and CD44 (Hope et al., 2004; Singh et al., 2004; Yuan et al., 2004; Collins et al., 2005) . Further studies of CSCs isolated from human prostate cancer, xenograft human prostate tumor, and some prostate cancer cell lines indicated that the CSCs fail to express the androgen receptor, but express such embryonic markers as SOX2, NANOG, OCT4, and the surface marker protein CD44 (Gu et al., 2007; Kasper, 2008) .
Additional reports demonstrated that CSCs have higher apoptosis-resistance properties than those of differentiated cancer cells Batra, 2006, 2007; Baumann et al., 2008) . These anti-apoptotic properties protect the CSCs from apoptosis stimuli and will eventually lead to cancer recurrence. As such, the exploration of effective methods either to decrease the apoptosis-resistant nature of CSCs or to induce the differentiation of them is a promising strategy for cancer therapy . In this regard, during the past few years, SOX2 has been intensively investigated and was found to contribute to tumorigenesis and recurrence of certain types of cancer (Chen et al., 2008; Saigusa et al., 2009) . Consequently, targeting of SOX2 may be an effective therapeutic strategy for cancer therapy; however, the function of SOX2 in apoptosisresistant nature of cancer cells and its underlying mechanism still need to be explored.
Prostate cancer is the second leading threat to men's health in the western world, and the therapeutic effects were always compromised by the appearance of hormone refractory cancer cells, leading eventually to the recurrence of cancer. Many factors may contribute to the apoptosis-resistant nature of prostate cancer and down-regulation of store-operated Ca 2+ entry (SOCE) was shown to be one of them (Bodding et al., 2003; Vanden Abeele et al., 2003a, b) . SOCE participates in a unique mechanism to regulate the communications between intracellular Ca 2+ stores and extracellular reservoirs, thus plays an important role in a variety of physiological and pathophysiological processes including apoptosis (Vanden Abeele et al., 2002; Feske, 2007) . SOCE is mediated by SOCE channels (SOCs), whose key components are Orai1 and STIM1: Orai1 is located on the plasma membrane working as a gate, whereas STIM1 is located in the ER membrane to sense the depletion of the ER Ca 2+ store, then interacts with Orai1 to allow the SOCE (Liou et al., 2005; Roos et al., 2005; Zhang et al., 2006) . The phenomenon of reduced SOCE was always observed when the character of prostate cancer changed from androgen dependent to hormone refractory. For example, Bcl-2 overexpression in LNCaP prostate cancer cells transforms them from an androgen dependent to an androgen independent phenotype by reducing the SOCE activity (Vanden Abeele et al., 2002) . Reduced function of SOCE was also demonstrated to increase apoptosis resistance of prostate cancer (Vanden Abeele et al., 2003b) . Vice versa, overexpression of STIM1 to increase SOCE activity could accelerate the apoptosis of epithelial cells (Chiu et al., 2008) . SOCE may work in many ways to regulate the apoptosis process. For example, SOCE was reported to functionally interact with Bax to accelerate the apoptosis process in NRP-154 prostate cancer cells (Li et al., 2008 (Li et al., , 2009 .
Since SOX2 is a key regulatory gene of CSCs and reduced SOCE activity plays an important role in apoptosis-resistant properties of prostate cancer, we hypothesized that SOX2 promotes the tumorigenesis process and increases apoptosis-resistance property in prostate cancer cells by reducing SOCE activity. Here we tested the hypothesis with immunohistochemical methods to specifically analyze the expression of SOX2 in human prostate tissues and tested SOX2's function in cultured androgen refractory human prostate cancer cell line DU145. Our results demonstrated that SOX2 contributed to the tumorigenesis of human prostate cancer and had the potential to serve as a marker to evaluate the progression of tumor malignancy. We also found that SOX2 increased DU145 cells' resistance to the apoptosis stimuli with reduced SOCE activity. These findings suggest that targeting of SOX2 may be a potentially useful strategy for improving prostate cancer therapy.
Results
SOX2 is specifically overexpressed in prostate cancer tissues with high Gleason score To determine whether SOX2 plays a role in the development of prostate carcinomas, we performed immunohistochemical analyses with a SOX2 specific antibody in tissue microarrays containing 224 samples of human normal/paracarcinomal, hyperplasia and different clinical degrees of human prostate cancer tissues. As shown in Figure 1A and 1B, strong expression of SOX2 was only detectable in prostate cancer tissues. We next investigate the relationship between SOX2 expression and development of prostate cancer ( Figure 1C ) and found that 92% of the analyzed tumor tissues showed SOX2-positive expression. In contrast, only 8% of normal/paracarcinomal or hyperplasia tissues were SOX2 positive, suggesting that SOX2 may contribute to the tumorigenesis of human prostate cancer. A further analysis of the relationship between SOX2 and clinical guidelines showed that SOX2 stainings became more intense with increased histologic grade ( Figure 1D) , and Gleason score of prostate cancer tissues ( Figure 1E) . The scatter plot assay demonstrated a close correlation between the average Gleason score and the expression level of SOX2 ( Figure 1F ). Since a higher Gleason grade indicates a worse prognosis, our results suggested that SOX2 may play an important role in the clinical progress of human prostate cancer and may contribute to the chemo-resistant nature of prostate cancer.
To further investigate the character of SOX2 in prostate cancer cells, western blotting analyses were performed to detect the expression level of SOX2 in BPH-1, LNCaP, PC3, and DU145 cell lines, among which BPH-1 is a human prostate hyperplasia cell line and the other three are well-characterized human prostate cell lines: LNCaP is hormone sensitive with low metastasis property, PC3 and DU145 are hormone refractory with higher metastasis and malignant properties (Mitchell et al., 2000) . As shown in Figure 2A , the expression of SOX2 was significantly increased in the malignant cell lines when compared with hyperplasia cell line, further indicated that SOX2 may play an important role in tumorigenesis of prostate cancer.
SOX2 is expressed in the cytosol and nuclei of prostate cancer cells After immunohistochemical analyses, we found an interesting phenomenon indicating that SOX2 was detectable in both the nuclei and cytosol of prostate cancer cells, which was in contrast to its reported localization in ES cells. To further reveal the localization of SOX2 in prostate cancer cells, we performed immunofluorescence staining of SOX2 in PC3 and DU145 cells and found that SOX2 was detectable in both the nuclei and cytosol of DU145 cells, but its expression level is very low in PC3 cells when compared with that in DU145 cells. To exclude the possibility of non-specific reaction by the anti-SOX2 antibody, we used the same antibody to detect the expression of SOX2 in J1 ES, an established mouse ES cell line, but found that SOX2 could only be detected in the nuclei fraction ( Figure 2B ). The cytosol and nuclear localization of SOX2 in prostate cancer cell lines was further confirmed by transfecting DU145 and PC3 cells with the EGFP tagged SOX2 using pCMS-SOX2-EGFP plasmid ( Figure 2C ).
Increased cell proliferation in DU145 cells with SOX2 overexpression
To investigate SOX2's function in the proliferation of prostate cancer cells, stable polyclonal cells with SOX2 overexpression (DU145-SOX2) were established. The overexpression of SOX2 was confirmed by western blotting ( Figure 3A ), statistical analysis showed that compared with mock plasmid transfected control cells (DU145-Con), the expression of SOX2 could be achieved by 4.3 folds in DU145-SOX2 cells. Cell growth curve showed that SOX2 increased the proliferation rate of DU145 cells, indicating SOX2 promotes cell proliferation property ( Figure 3B ). To further analyze SOX2's effect on cell cycle, DU145 cells were double stained with FITC-labeled BrdU, which incorporates with the cells in S phase and 7-amino-actinomycin (7-AAD), which stains total DNA content. Our results indicated that SOX2 promotes DNA synthesis in DU145 cells ( Figure 3C and 3D).
Increased apoptosis-resistant properties in DU145 cells with SOX2 overexpression Since SOX2 obviously increased the growth rate of DU145 cells, we determined whether SOX2 contributes to the chemo-resistant nature of prostate cancers. To this end, DU145 cells were treated with thapsigargin (TG) or cisplatin (CDDP) in culture medium for 24 h under normal culture conditions, then subjected to flow cytometry analysis by staining them with propidium iodide (PI), which can penetrate the membranes of both dead and damaged cells, and FITC conjugated Annexin V, which binds to cells with translocated phosphatidylserine in plasma during early stage of apoptosis. TG was reported to bind to the SERCA pump in the ER to release intracellular Ca 2+ and trigger the apoptosis process (Duncan et al., 1997) ; CDDP is a platinum-based chemotherapy drug that crosslinks with DNA and thus interferes with cell division to trigger apoptosis (Pruefer et al., 2008) . As shown in Figure 4A , less apoptotic cells in the early phase and late phase could be observed in DU145-SOX2 cells. Statistical results showed that SOX2 decreased the percentage of apoptotic cells by 60% under both TG and CDDP treatment when compared with DU145-Wt and DU145-Con cells ( Figure 4B ), indicating that SOX2 increases prostate cancer cells' resistance against apoptotic stimuli and chemotherapy.
Another way to test the cell's sensitivity to apoptotic stimuli is to detect the cleavage of caspase 3 during apoptosis. As shown in Figure 4C , the cleavage form of caspase 3 was only detectable at 24 h after CDDP treatment in DU145-SOX2 cells, which was obviously delayed than those observed in DU145-Wt and DU145-Con cells. This observation further supports the contention that SOX2 contributes to the anti-apoptotic property of DU145 cells and that targeting of SOX2 may be a promising strategy for prostate cancer therapy.
Knock down of SOX2 increases the apoptotic sensitivity of DU145 cells The finding that SOX2 increased the chemo-resistant property of DU145 cells suggested that down-regulation of SOX2 can be a promising strategy for prostate cancer therapy. To test this contention, stable DU145 cells with doxycycline (Dox) inducible expression of shRNA targeting SOX2 were established (DU145-shRNA-SOX2). Mock pSingle-tTS plasmid-transfected stable cells served as a control (DU145-shRNA-Con). Western blotting results showed that shRNA1 and shRNA2 had 50% and 30% down-regulatory efficiency individually for SOX2 when compared with DU145-shRNA-Con cells ( Figure 4D ). Consequently, shRNA1 was employed in later experiments. Figure 4E showed that early cleavage of caspase 3 could be observed in DU145-shRNA1-SOX2 cells corresponding to TG treatment, indicating that down-regulation of SOX2 increases the cell's sensitivity to apoptotic stimuli.
SOX2 down-regulation in vivo decreases tumorigenesis and increases apoptotic sensitivity of DU145 cells Having identified SOX2's contribution to tumorigenesis and apoptosis resistance of human prostate cancer in vitro, we consequently tested the function of SOX2 in prostate cancer in vivo.
To this end, 6-8-weeks old NOD/SCID male mice were separated into three groups and treated according to the schematic experimental protocol as shown in Figure 5A . Obvious xenograft tumor could be detected after 20 days of inoculation; the mice were then treated with different drinking water components. No significant difference in tumor growths could be observed between the DU145-shRNA-Con xenograft mice (group 1) and the DU145-shRNA1-SOX2 xenograft mice that were not supplied with Dox in the drinking water (group 2), but retarded tumor growths were observed in DU145-shRNA1-SOX2 xenograft mice that were supplied with Dox in the drinking water (group 3) when compared with those two groups. These results indicate that the Dox-inducible pSingle-tTS-shRNA system works in vivo and the down-regulation of SOX2 can retard the growth rate of tumor, thus suggesting that SOX2 regulates tumorigenesis of prostate cancer ( Figure 5B) .
To further test SOX2's function in the apoptosis-resistant property of prostate cancer in vivo, we simulated the chemotherapy experiments. Specifically, the DU145-shRNA1-SOX2 xenograft mice of group 2 started to be supplied with Dox from the 40th day after tumor inoculation and the mice from groups 1 and 2 were treated with three times of CDDP from day 44. Our results showed that: first, down-regulation of SOX2 significantly increased the tumor's sensitivity to the chemotherapy since the tumor sizes in the DU145-shRNA1-SOX2 xenograft mice were significantly reduced at day 56 when compared with the DU145-shRNA-Con xenograft mice as the control ( Figure 5C and  5D) ; the down-regulation of SOX2 was further confirmed by immunohistochemistry method in tumor tissues of two groups of DU145-shRNA1-SOX2 xenograft mice ( Figure 5E ). The apoptosis results were confirmed by TUNEL staining (Figure 5F ), which revealed that more apoptotic cells could be observed in the tumor tissues of DU145-shRNA1-SOX2 xenograft mice that were treated with Dox and CDDP than those of control mice that were treated under the same condition ( Figure 5G) . Second, the combination of SOX2 down-regulation and chemotherapy was an effective strategy in prostate cancer therapy, since that could decrease the tumor to the same size in 12 days as another group of DU145-shRNA1-SOX2 xenograft mice (group 3) that has been treated only with SOX2 down-regulation for 36 days ( Figure 5C and 5D ).
Reduced SOCE activity in DU145 cells overexpressing SOX2
Since SOX2 is an important transcriptional regulator, it may regulate certain genes that are related to the apoptosis pathway. We first detected the expression of key anti-apoptotic proteins of Bcl-2 protein family in DU145 cells by western blotting. However, as shown in Figure 6A , the protein expression levels of Bcl-xL, Bcl-2, and Mcl-1 did not show any significant difference between DU145-SOX2 and the DU145-Con, DU145-Wt cells, suggesting that other adaptive change must exist in the DU145-SOX2 cells that protect them from undergoing apoptosis.
Based on previous studies reporting that the perturbed intracellular Ca 2+ signal and SOCE activity contribute to the anti-apoptotic property in prostate cancer (Vanden Abeele et al., 2002 , 2003b Li et al., 2008) , we proposed that altered Ca
2+
homeostasis and SOCE activity may contribute to the apoptosis resistance of DU145-SOX2 cells. To test this contention, intracellular Ca 2+ homeostasis and the function of SOCE was measured in DU145 cells. As shown in Figure 6B , 1 mM TG was added to the extracellular solution 60 sec after incubation in the extracellular solution without Ca 2+ . Because TG passively depletes the ER Ca 2+ store, which in turn triggers the open of SOCs and activation of SOCE, CaCl 2 was added to the extracellular solution to the final concentration of 4 mM after 250 sec of TG treatment. The extracellular Ca 2+ then passed through opened SOCs and entered into the cell, leading to an increase in F 340 /F 380 . When compared with the DU145-Wt and DU145-Con, the resting cytosolic
] i ) ( Figure 6C ) and TG-induced Ca
release from the ER did not show obvious difference ( Figure 6D) ; however, the SOCE activity was significantly reduced in DU145-SOX2 cells ( Figure 6E ). These results suggested that the compromised expression of SOX2 increases anti-apoptotic property of DU145 cells by reducing SOCE activity.
Down-regulation of Orai1 in DU145 cells with SOX2 overexpression
In view of our findings on SOX2's effect on SOCE activity in DU145 cells, we further determined the molecular mechanism underlying this phenomenon. For this purpose, RT-PCR was performed and our results showed that the mRNA expression level of Orai1 was significantly reduced in DU145-SOX2 cells ( Figure 6F ). This result was further confirmed by western blotting ( Figure 6G ), vice versa the expression level of Orai1 increased when SOX2 was down-regulated ( Figure 6H) . Together, these studies demonstrated that SOX2 downregulates SOCE activity by inhibiting the expression of Orai1 and suggest this may be one of the important mechanisms that contribute to the anti-apoptotic properties of SOX2 in DU145 cells.
Discussion
In this paper, we used immunohistochemistry to investigate the expression of SOX2 in human prostate tissues and found the overexpression of SOX2 to be closely correlated with the clinical progress of prostate cancer. A further analysis of the function of SOX2 in chemo-resistant properties of prostate cancer cells by in vitro and in vivo experiments revealed a possible underlying mechanism of SOX2 increasing the anti-apoptosis properties of DU145 cells is the down-regulation of SOCE activity.
One of the key observations in the present study is that SOX2 could be potentially developed as a pathological criterion to distinguish tumor from non-tumor prostate tissues and to predicate the prognosis of prostate tumor, since strong expression of SOX2 could only be detected in most of the tumor tissues in correlation with increased histologic grade and Gleason score.
Another interesting finding was the location of SOX2 in prostate cancer tissues and cell lines. The nuclei localized SOX2 in prostate cancer cells may function as a transcriptional regulator, however, the function of SOX2 in the cytosol of prostate cancer cells and the factors that may regulate the cellular location of SOX2 still need to be further investigated. The progress in revealing these underlying mechanisms will deepen our understanding of SOX2's function in cancer cells.
The third important finding of this study was the identification of the regulatory effects of SOX2 on cell growth and antiapoptosis properties in prostate cancer. Our data demonstrated that the stem cell marker SOX2 regulated cell growth by promotion of cell proliferation and enhancement of DNA synthesis in DU145 cells. SOX2 was also shown to play an important role in increasing the chemo-resistant property of prostate cancer cells. Together, our findings support the concept that SOX2 is one of the key factors that may contribute to tumor recurrence. In this regard, it was interesting to find that although the expression of main anti-apoptotic proteins such as Bcl-2, Bcl-xL and Mcl-1 did not significantly change in DU145-SOX2 cells, an alteration in the SOCE activity was observed. These findings further support the important role for SOCE in the apoptosisresistant function of SOX2 in DU145 cells.
Previous studies demonstrated the important contribution of SOCE to the signaling cascade of apoptosis, in such cells, additional sustained SOCE besides ER Ca 2+ store depletion was required for the initiation of apoptosis. Our study showed that the SOCE was significantly reduced in DU145 cells with sustained overexpression of SOX2 and demonstrated the transcriptional regulation of SOX2 on Orai1, one key component of SOCs. Our data support the concept that targeting SOX2 to increase the SOCE activity may be a potential strategy in prostate cancer therapy.
Materials and methods
Gene cloning cDNA of human SOX2 was subcloned into the pCDNA3.1(2) expression vector (Invitrogen, Carlsbad, CA) between the NheI and NotI restriction sites. Two shRNAs targeting human SOX2 designed as shRNA1-SOX2: (Top) 5 ′ -tcgagGCCAAGACGCTCATGAA
TAACTGTCCACc-3 ′ were subcloned into the Dox-inducible pSingle-tTS-shRNA expression vector between the XhoI and HindIII restriction sites.
Cell culture DU145 cells were purchased from ATCC, whereas BPH-1, LNCaP, PC3, and J1 ES cells were kindly gifts from Drs Ju Zhang and Lin Liu (College of Life Sciences, Nankai University, Tianjin, China). Parental DU145 cells (DU145-Wt) were transfected with pCDNA3.1(2)-SOX2 or pSingle-shRNA-SOX2 cDNA by Lipofectamine 2000 (Invitrogen), followed by clonal selection using 500 mg/ml neuromycin to generate polyclone of DU145 cells with stable SOX2 overexpression (DU145-SOX2) or downregulation (DU145-shRNA-SOX2). Cells were maintained in RIPM1640 media supplemented with 10% fetal bovine serum in the presence of 100 U/ml penicillin-streptomycin and 500 mg/ ml neuromycin. For control purposes, DU145-Wt cells were transfected with the mock plasmids and subjected to identical clonal selection procedures.
Immunohistochemistry and tissue microarrays
High-density tissue microarrays were purchased from Chaoying Biotechnology Company (Shanxi, China). Standard biotin -avidin complex immunohistochemistry was performed. Prostate tissues were visualized by hematoxylin and eosin (H/E) staining, and the expression of SOX2 in tissues was detected by the affinitypurified monoclonal mouse antibody against SOX2 (Abcam, Inc., Cambridge, UK). The expression level of SOX2 in tissue microarray was scored according to the percentage of SOX2-positive cells in each prostate tissue. Specifically, a percentage ,10% was judged negative, ≥10% was positive, 10%-29% was judged weak, 30%-49% was judged moderate, and ≥50% was judged as strong immunostaining intensity. The scoring was performed blindly without knowledge of the Gleason score and pathological grade.
Immunofluorescent and confocal images Cells were grown on glass coverslip until 60%-80% confluent, fixed with acetone and penetrated with Triton X-100. DU145, PC3, and J1 ES cells were each treated with polyclonal anti-SOX2 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) overnight at 48C, followed by incubation with Alexa Fluor 546 goat anti-rabbit IgG (Molecular Probes, Eugene, OR) at room temperature for 1 h, then incubated with DAPI and visualized with a Lecia laser scanning microscope (TCS-SP2-AOBS-MP; Leica Microsystems CMS, GmbH Mannheim, Germany).
Western blotting
Cell lysates from different DU145 cell lines were prepared with the radioimmunoprecipitation assay buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, and 1 mM Na 3 VO 4 , pH 7.4) in the presence of protease inhibitor cocktails (Sigma, Saint Louis, MS Flow cytometry analysis of cell cycle and apoptosis Following culture of DU145 cells in the absence of FBS for 12 h, cells were 'pulsed' with 10 mM 5-bromo-2-deoxyuridine (BrdU) for 24 h at 378C, and cell cycle assay was performed by using the Cytofix/cytoperm kit (BD Biosciences, San Jose, CA) following manufacturer's instructions. For apoptosis assay, the apoptotic cells were stained with PI and Annexin-V-FITC (KeyGen Biotech Co., Nanjing, China). Flow cytometry analysis was performed by FACS Calibur cytometer (BD Biosciences), in which a minimum of 10000 cells were assayed. Tumor xenograft studies All experiments involving mice were carried out in strict accordance with institutional and local government guidelines on handling of laboratory animals. Male NOD/SCID mice were xenografted with 3 × 10 6 DU145 cells each subcutaneously at right axilla, respectively. The mice were fed with 0.05% sucrose or with 0.2 mg/ml Dox in drinking water, which was changed freshly every 4 days. CDDP was administered i.p. every 4 days at a dose of 5 mg/kg body weight to the mice from indicated time. Tumor volume (mm 3 ) was measured with calipers and calculated by using the standard formula: length × width 2 /2.
RT-PCR

TUNEL staining
Paraffin-embedded tissue slides were prepared from the xenograft prostate tumors. DeadEnd TM Fluorometric TUNEL System kit (Promega) was applied for TUNEL staining. Experiment procedure was performed according to the manuscript instruction. DAPI was used to stain the nuclei, and the tissue slides were subjected to Olympus BX51 Epi-fluorescent microscopy under a 20× objective (Olympus Co., Tokyo, Japan).
Intracellular Ca
2+ measurement DU145 cells grown on coverslips were placed in a balanced salt solution (140 mM NaCl, 2.5 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 12 mM D-glucose, and 10 mM HEPES, pH 7.2) and loaded with 3 mM Fura-2/acetoxymethylester in the presence of 2 mM Ca
2+
for 45 min at 378C. The dye was allowed to de-esterify for 15 min at 258C. Cells were then washed and changed to an extracellular solution with 2 mM EGTA and without Ca 2+ . Ca 2+ measurements were performed with an InCyt dual-wavelength fluorescence imaging system (Intracellular Imaging, Inc., Cincinnati, OH). The fluorescent intensity of Fura-2 in each cell was monitored and recorded at 340 and 380 nm. The fluorescence intensity ratio represented by F 340 /F 380 was used as an indicator of changes in cytosolic Ca 2+ concentration. All measurements shown are averages of 35-45 cells from a minimum of three experiments. Figure 1 were plotted as mean and others as mean + SE. Significance was determined by x 2 test in Figure 1 and others were determined by Student's t-test. A value of P , 0.05 was used as criterion for statistical significance. *Significant difference with P , 0.05, **significant difference with P , 0.01.
Statistical analysis Values in
